# Editorial: Neuroprotection and disease modification in Parkinson's disease: Volume II

Matilde Otero-Losada, Paolo Gubellini, Francisco Capani, Santiago Perez-Lloret

## ► To cite this version:

Matilde Otero-Losada, Paolo Gubellini, Francisco Capani, Santiago Perez-Lloret. Editorial: Neuroprotection and disease modification in Parkinson's disease: Volume II. Frontiers in Pharmacology, 2023, 13, 10.3389/fphar.2022.1121513. [https://doi.org/10.3389/fphar.2022.1121513](https://doi.org/10.3389/fphar.2022.1121513)

HAL Id: hal-04286567

https://amu.hal.science/hal-04286567v1

Submitted on 15 Nov 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons CC BY 4.0 - Attribution - International License
<figure><img src="image_2.png" /></figure>

OPEN ACCESS

EDITED AND REVIEWED BY
Nicholas M. Barnes,
University of Birmingham,
United Kingdom

*CORRESPONDENCE
Matilde Otero-Losada,
Molly1063@gmail.com

SPECIALTY SECTION
This article was submitted to
Neuropharmacology,
a section of the journal
Frontiers in Pharmacology

RECEIVED 11 December 2022

ACCEPTED 19 December 2022

PUBLISHED 09 January 2023

CITATION

Otero-Losada M, Gubellini P, Capani F and Perez-Lloret S (2023), *Editorial: Neuroprotection and disease modification in Parkinson's disease: Volume II*. *Front. Pharmacol.* 13:1121513. doi: 10.3389/fphar.2022.1121513

COPYRIGHT

© 2023 Otero-Losada, Gubellini, Capani and Perez-Lloret. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Editorial: Neuroprotection and disease modification in Parkinson's disease: Volume II

Matilde Otero-Losada¹*, Paolo Gubellini², Francisco Capani¹,³ and Santiago Perez-Lloret⁴,⁵,⁶

¹Consejo Nacional de Investigaciones Científicas y Técnicas, Universidad Abierta Interamericana-Centro de Altos Estudios en Ciencias Humanas y de La Salud, UAI-CAECIHS CONICET, Buenos Aires, Argentina, ²CNRS, IBDM, UMR7288, Aix-Marseille University, Marseille, France, ³Instituto de Ciencias Biomedicas, Facultad de Ciencias de la Salud, Universidad Autonoma de Chile, Santiago de Chile, Chile, ⁴Observatorio de Salud Pública, Pontificia Universidad Católica Argentina (UCA), Buenos Aires, Argentina, ⁵Department of Physiology, Faculty of Medicine, University of Buenos Aires (UBA), Buenos Aires, Argentina, ⁶Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina

KEYWORDS

neuroprotection, disease-modifying therapeutics, pathophysiology, natural history, Parkinson's disease

## Editorial on the Research Topic

### Neuroprotection and disease modification in Parkinson's disease: Volume II

Parkinson's disease (PD) is the second prevailing neurodegenerative disease worldwide after Alzheimer's. Nearly 1% of seniors over 65 suffer from this disease, and as old population grows rapidly, so does PD incidence. Early onset PD, before the 50s, is usually inherited, likely related to specific gene mutations. Added to the characteristic symptoms of PD, v.g., bradykinesia, shaking, stiffness, and handicapped balance and coordination, innumerable non-motor symptoms like changes in mood, sleep patterns and quality, and autonomic alterations impair patients' life quality. Current treatments aim to mitigate PD symptoms, not decelerating disease progression. So far, no preventing approach is available against PD.

Current pharmacology in this field has a clear priority, which is to identify or develop drugs and therapies to hold PD progression. Basic research to test the potential of new molecules and strategies in neuroprotection is thus mandatory.

This Research Topic addresses some new pharmacological neuroprotective and disease-modifying strategies for PD, including possible target pathways, and effects on humans. We trust this updated information may help to devising new therapeutic strategies to prevent or delay PD onset and progression.

Subjects covered in this Research Topic are:

*Peripheral Neuroprotective and Immunomodulatory Effects of 5α-Reductase Inhibitors in Parkinson's Disease Models.* After finding an immunomodulatory effect of female hormones to treat enteric neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD, Poirier et al. tested the hypothesis of obtaining similar neuroprotection by affecting steroidogenesis with two 5α-reductase inhibitors, finasteride and dutasteride. They found that dutasteride treatment prevented enteric neuronal damage in the MPTP mouse model, partly via anti-inflammatory and mitochondrial effects. Dutasteride might thus constitute a promising drug for treating enteric neuroinflammation in early PD (Perez-Pardo et al., 2019; Poirier et al., 2016).

*Characterization of Nasco grape pomace-loaded nutriosomes and their neuroprotective effects in the MPTP mouse model of Parkinson's disease.* The neuroprotective effects of
Nasco pomace, rich in the antioxidant polyphenols gallic acid, catechin, epicatechin, procyanidin B2, and quercetin, were investigated in the subacute MPTP mouse model of PD. Nasco nutriosomes or Nasco suspension was administered intragastrically. The results proved neuroprotection, validating the effectiveness of the nutriosome preparation over suspension as an innovative nano-drug delivery system for in vivo administration (Parekh et al.) (Pazos-Tomas et al., 2020; Shahpiri et al., 2016).

Preclinical reserpine models recapitulating motor and non-motor features of Parkinson's disease: Roles of epigenetic upregulation of alpha-synuclein and autophagy impairment. Li et al. used a preclinical animal model using reserpine to recapitulate motor and non-motor PD symptoms. Chronic reserpine exposure caused hypomethylation of the alpha-synuclein gene, upregulated its expression, and elevated the LC3-II/LC3-I ratio and expression of p62 in mice substantia nigra. Chronic reserpine exposure epigenetically raised alpha-synuclein expression, likely via decreasing DNA methylation and inducing autophagic impairment in vitro and in vivo (Chia et al., 2020; Fernandes et al., 2012).

Motor cortico-nigral and cortico-entopeduncular information transmission and its modulation by buspirone in control and after dopaminergic denervation. The nigrostriatal dopamine (DA) and the activation of 5-HT1A receptors, distributed in the basal ganglia, may modulate cortical information transmission. The authors investigated the effect of buspirone (5-HT1A receptor partial agonist) and WAY-100635 (5-HT1A receptor antagonist) on cortico-nigral and cortico-entopeduncular transmission in normal and DA loss conditions. In control condition, buspirone potentiated direct pathway transmission and DA loss modulated responses related to the hyperdirect pathway. The results may help to clarify the role of 5-HT1A receptors and DA in motor cortico-basal ganglia circuitry functionality (Vegas-Suárez et al. ) (Miguelez et al., 2014; Suarez et al., 2020).

Epigallocatechin-3-gallate: A phytochemical as a promising drug candidate for the treatment of Parkinson's disease (frontiersin.org). Wang et al. compiled recent updates and knowledge of the molecular mechanisms underlying the neuroprotective effects of Epigallocatechin 3-gallate (EGCG), an abundant polyphenolic component derived from green tea extract in PD. They focused on EGCG effects on apoptosis, oxidative stress, inflammation, ferroptosis, dopamine synthesis modulation, and α-synuclein the aggregation. So far, the evidence reveals a promising role of EGCG in neuroprotection in PD treatment (Mahoney-Sánchez et al., 2021; Martinez-Perez et al., 2018).

Adverse event profiles of adjuvant treatment with opicapone in Parkinson's disease: A systematic review and meta-analysis. Tolerability and treatment-related adverse events of short-term (<6 months) and long-term (≥6 months) treatment with opicapone, a novel third-generation catechol-O-methyltransferase inhibitor, were

compared in PD patients. Overall, opicapone was usually well-
tolerated, with a low risk of adverse events including dyskinesia
(16.1%), dry mouth (12.1%), decreased medication effect (12.1%),
exacerbated PD (7.8%), increased blood creatine phosphokinase level
(7.4%), nausea (6.1%) and insomnia (5.1%) (Xie et al.) (Żegleń et al.,
2022; Takeda et al., 2021).

Doxycycline attenuates l-DOPA-induced dyskinesia through an anti-inflammatory effect in a hemiparkinsonian mouse model. Targeting neuroinflammation seems promising in alleviating l-DOPA-induced dyskinesia (LID) in PD. In this study, doxycycline, a semisynthetic brain-penetrant tetracycline antibiotic with interesting anti-inflammatory properties, was found to prevent LID regardless of the severity of dopaminergic lesioning in an experimental mice model, likely due to its anti-inflammatory effects. Doxycycline poses as an attractive and alternative treatment for LID in PD (dos Santos Pereira et al.) (Wang et al., 2017; Santa-Cecilia et al., 2016).

Cutting edge research is crucial for identifying and testing new
compounds and strategies for, if healing is not possible, at the least,
alleviating PD nuisance. To end, a few words, recalling Hippocrates: "I
will remember that there is art to medicine as well as science, and that
warmth, sympathy, and understanding may outweigh the surgeon's
knife or the chemist's drug" [Greek Medicine-The Hippocratic Oath
(nih.gov)].

Author contributions

MO-L wrote the editorial draft; MO-L, PG, SP-L and FC corrected and approved the final version.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors
and do not necessarily represent those of their affiliated
organizations, or those of the publisher, the editors and the
reviewers. Any product that may be evaluated in this article, or
claim that may be made by its manufacturer, is not guaranteed or
endorsed by the publisher.

References

Chia, S. J., Tan, E. K., and Chao, Y. X. (2020). Historical perspective: Models of Parkinson's disease. *International Journal of Molecular Sciences*. 21, E2464. doi:10.3390/ijms21072464

Fernandes, V. S., Santos, J. R., Leão, A. H., Medeiros, A. M., Melo, T. G., Izídio, G. S., et al. (2012). Repeated treatment with a low dose of reserpine as a progressive model of Parkinson's disease. *Behavioural Brain Research*. 231, 154–163. doi:10.1016/j.bbr.2012.03.008

Greek Medicine (2002). Greek medicine-the hippocratic oath (nih.gov). Available at: https://www.nlm.nih.gov/hmd/greek/greek_oath.html

Mahoney-Sánchez, L., Bouchaoui, H., Ayton, S., Devos, D., Duce, J. A., and Devedjian, J. C. (2021). Ferroptosis and its potential role in the physiopathology of Parkinson's Disease. *Progress in Neurobiology*. 196, 101890. doi:10.1016/j.pneurobio.2020.101890

Martinez-Perez, D. A., Jimenez-Del-Rio, M., and Velez-Pardo, C. (2018). Epigallocatechin-3-Gallate protects and prevents paraquat-induced oxidative stress and neurodegeneration in knockdown dj-1-β Drosophila melanogaster. *Neurotoxicity Research*. 34 (3), 401–416. doi:10.1007/s12640-018-9899-x

Miguelez, C., Morera-Herreras, T., Torrecilla, M., Ruíz-Ortega, J. A., and Ugedo, L. (2014). Interaction between the 5-HT system and the basal ganglia: Functional implication and therapeutic perspective in Parkinson's disease. *Frontiers in Neural Circuits*. 8, 21. doi:10.3389/fncir.2014.000021

Pazos-Tomas, C. C., Cruz-Venegas, A., Pérez-Santiago, A. D., Sánchez-Medina, M. A., Matías-Pérez, D., García-Montalvo, I. A., et al. (2020). Vitis vinifera: An alternative for the prevention of neurodegenerative diseases. *Journal of Oleo Science*. 69, 1147–1161. doi:10.5650/JOS.ESS20109
Perez-Pardo, P., Dodiya, H. B., Engen, P. A., Forsyth, C. B., Huschens, A. M., Shaikh, M., et al. (2019). Role of TLR4 in the gut-brain axis in Parkinson's disease: A translational study from men to mice. *Gut* 68, 829-843. doi:10.1136/gutjnl-2018-316844

Poirier, A. A., Côté, M., Bourque, M., Morissette, M., Di Paolo, T., and Soulet, D. (2016b). Neuroprotective and immunomodulatory effects of raloxifene in the myenteric plexus of a mouse model of Parkinson's disease. *Neurobiology of Aging*. 48, 61-71. doi:10.1016/j.neurobiolaging.2016.08.004

Santa-Cecilia, F. V., Socias, B., Ouidja, M. O., Sepulveda-Diaz, J. E., Raisman-Vozari, R., Acuna, L., et al. (2016). Doxycycline suppresses microglial activation by inhibiting the p38 MAPK and NF-κB signaling pathways. *Neurotox* 29, 447-459. doi:10.1007/s12640-015-9592-2

Shahpiri, Z., Bahramsooltani, R., Farzaei, M. H., Farzaei, F., and Rahimi, R. (2016). Phytochemicals as future drugs for Parkinson's disease: A comprehensive review. *Nature Reviews Neuroscience*. 27 (6), 651-668. doi:10.1515/revneuro-2016-0004

Suarez, L. M., Solis, O., Sanz-Magro, A., Alberquilla, S., and Moratalla, R. (2020). Dopamine D1 receptors regulate spines in striatal direct-pathway and indirect-pathway neurons. *Movement Disorders*. 35, 1810-1821. doi:10.1002/MDS.28174

Takeda, A., Takahashi, R., Tsuboi, Y., Nomoto, M., Maeda, T., Nishimura, A., et al. (2021). Randomized, controlled study of opicapone in Japanese Parkinson's patients with motor fluctuations. *Movement Disorders*. 36, 415-423. doi:10.1002/mds.28322

Wang, N., Tian, X., Chen, Y., Tan, H. Q., Xie, P. J., Chen, S. J., et al. (2017). Low dose doxycycline decreases systemic inflammation and improves glycemic control, lipid profiles, and islet morphology and function in db/db mice. *Scientific Reports*. 7, 14707. doi:10.1038/s41598-017-14408-7

Żegleń, M., Śladowska, K., Kawalec, P., and Brzostek, T. (2022). Opicapone as an add-on to levodopa for reducing end-of-dose motor fluctuations in Parkinson's disease: A systematic review and meta-analysis. *Journal of Comparative Effectiveness Research*. 11, 889-904. doi:10.2217/cer-2022-0031